Protocols
AMG-757-20210004 Phase III OPEN TO ACCRUAL
A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared with Standard of Care in Subjects with Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy (DeLLphi-304)
HARPOON-HPN328-4001 Phase I/II OPEN TO ACCRUAL
A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN328 Monotherapy and HPN328 with Atezolizumab in Patients with Advanced Cancers Associated with Expression of Delta-like Canonical Notch Ligand 3 (DLL3)
HOFFMANN-BO41932-TAPISTRY Phase II OPEN TO ACCRUAL
Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
MIRATI-1719-001 Phase I/II OPEN TO ACCRUAL
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion
NRG-GY022 Phase I OPEN TO ACCRUAL
Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin
NRG-LU007 Phase II/III OPEN TO ACCRUAL
Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
SWOG-S1827 Phase III OPEN TO ACCRUAL
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)